Brief: Alumis, Acelyrin To Merge Creating A Late-Stage Clinical Biopharma Company
06/02/2025 22:56
Feb 6 (Reuters) - Alumis Inc ALMS.O :
* ALUMIS AND ACELYRIN TO MERGE CREATING A LATE-STAGE
CLINICAL
BIOPHARMA COMPANY DEDICATED TO INNOVATING, DEVELOPING AND
COMMERCIALIZING TRANSFORMATIVE THERAPIES FOR IMMUNE-MEDIATED
DISEASES
Source text: ID:nGNX36S1bS
Further company coverage: ALMS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial